Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,532.00    -22.00 (-0.86%)
Bid:
2,530.00
Ask:
2,532.00
Spread: 2.00 (0.079%)
Market Cap: £8.13b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

30 Jun 2022 07:00

RNS Number : 7013Q
Bunzl PLC
30 June 2022
Β 

30 June 2022

Β 

BUNZL PRE-CLOSE STATEMENT

Β 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2022.

Β 

The Group is expected to deliver very strong growth over the period, reflecting the resilience and strength of the Bunzl business model. Group revenue in the first half is expected to increase year-on-year by approximately 16% at actual exchange rates and by 12-13% at constant exchange rates1, with inflation continuing to drive underlying revenue growth and the impact of acquisitions further supplementing growth. Group adjusted operating margin for the first half is expected to be slightly higher than historical annual levels.

Β 

Across our business areas inflation remains the key driver of performance. Very strong revenue growth has been maintained in North America over the period and negotiations with our largest customer are constructive and ongoing. Continental Europe similarly maintained strong momentum, whilst the UK & Ireland's operating margin continues to see year-on-year improvement alongside very strong base business recovery. Rest of the World's revenue growth has been moderate, with very strong growth in Asia Pacific partially offset by the expected decline in Covid-19 related sales in Latin America.

Β 

The Group is upgrading its guidance for the year on the basis of very strong revenue growth to date and announced acquisitions. At constant exchange rates the Group now expects very good revenue growth in 2022, driven by good organic revenue growth and the positive contribution of acquisitions announced in the last 12 months. Growth of the base business is expected to be only partially offset by the further normalisation of sales of Covid-19 related products, albeit these are expected to remain ahead of 2019 levels. We continue to expect Group operating margin in 2022 to be slightly higher than historical levels.

Β 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

Β 

"Bunzl has delivered another period of strong growth. We continue to demonstrate the strength of our business model, supported by the depth and resilience of our supply chains and the agility of our people who have responded to the inflationary environment so successfully. Our acquisition momentum remains strong, with our active pipeline supported by a strong balance sheet."

Β 

Β 

Note:

1. The number of trading days will not have an impact on growth over the period.Β 

Β 

Β 

Enquiries:

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

Tulchan

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTBUGDLUSDDGDC
Date   Source Headline
5th Jan 20235:36 pmRNSDirector/PDMR Shareholding
3rd Jan 202311:43 amRNSTotal Voting Rights
21st Dec 20227:00 amRNSTrading Statement
20th Dec 20227:00 amRNSAcquisition
14th Dec 20228:00 amRNSAdditional Listing
8th Dec 202212:56 pmRNSHolding(s) in Company
5th Dec 20229:45 amRNSDirector/PDMR Shareholding
1st Dec 20222:34 pmRNSTotal Voting Rights
29th Nov 20223:21 pmRNSDirector/PDMR Shareholding
11th Nov 20229:00 amRNSPublication of Admission Particulars
4th Nov 202212:08 pmRNSDirector/PDMR Shareholding
2nd Nov 20224:20 pmRNSDirector/PDMR Shareholding
1st Nov 20223:00 pmRNSTotal Voting Rights
1st Nov 202210:00 amRNSBlock listing Interim Review
20th Oct 20227:00 amRNSTrading Statement
11th Oct 20227:00 amRNSInvestor event
7th Oct 20224:11 pmRNSDirector/PDMR Shareholding
4th Oct 20224:54 pmRNSDirector/PDMR Shareholding
3rd Oct 20223:13 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSHolding(s) in Company
7th Sep 202210:59 amRNSDirector/PDMR Shareholding
1st Sep 202211:08 amRNSTotal Voting Rights
31st Aug 20221:46 pmRNSDirector/PDMR Shareholding
30th Aug 202210:00 amRNSDividend Declaration
30th Aug 20227:00 amRNSHalf-year Report
4th Aug 20229:19 amRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSAcquisition
1st Aug 20223:07 pmRNSTotal Voting Rights
1st Aug 202210:00 amRNSDirector Declaration
29th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
19th Jul 20227:00 amRNSDirectorate Change
12th Jul 202210:32 amRNSDirector/PDMR Shareholding
6th Jul 20225:12 pmRNSDirector/PDMR Shareholding
1st Jul 20222:18 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSTrading Statement
14th Jun 20227:00 amRNSAcquisition
8th Jun 202212:44 pmRNSDirector/PDMR Shareholding
1st Jun 202210:42 amRNSTotal Voting Rights
11th May 20228:00 amRNSAdditional Listing
5th May 202211:00 amRNSDirector/PDMR Shareholding
3rd May 202211:00 amRNSTotal Voting Rights
3rd May 202210:00 amRNSBlock listing Interim Review
28th Apr 20228:00 amRNSAdditional Listing
20th Apr 20225:17 pmRNSResult of AGM
20th Apr 20227:00 amRNSTrading Statement
19th Apr 20224:59 pmRNSDirector/PDMR Shareholding
8th Apr 20225:37 pmRNSDirector/PDMR Shareholding
8th Apr 20225:36 pmRNSDirector/PDMR Shareholding
7th Apr 20222:45 pmRNSDirector/PDMR Shareholding
5th Apr 20224:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.